The downregulation of DDX5 by sorafenib, as observed in our studies, activates Wnt/β-catenin signaling leading to ferroptosis escape [7], a mechanism implicated in acquired cancer drug resistance [12, 13]. The gene discussed is DDX5; the disease is cancer.